Redhill Biopharma Ltd (RDHL)

8.90
0.12 1.33
NASDAQ : Health Care
Prev Close 9.02
Open 8.90
Day Low/High 8.90 / 9.14
52 Wk Low/High 8.10 / 17.09
Volume 56.40K
Avg Volume 65.40K
Exchange NASDAQ
Shares Outstanding 17.06M
Market Cap 153.86M
EPS -2.30
P/E Ratio 47.47
Div & Yield N.A. (N.A)

Latest News

RedHill Biopharma Receives Notice Of Allowance For A New U.S. Patent Covering Its Combination Therapy For Hard-to-Treat Cancers

RedHill Biopharma To Present At The Cantor Fitzgerald Global Healthcare Conference
RedHill Biopharma Initiates Promotion Of Esomeprazole Strontium Delayed-Release Capsules 49.3 Mg In The U.S.

RedHill Biopharma Initiates Promotion Of Esomeprazole Strontium Delayed-Release Capsules 49.3 Mg In The U.S.

RedHill Biopharma To Present At The 10th Annual BioPharm America International Partnering Conference

RedHill Biopharma To Present At The 10th Annual BioPharm America International Partnering Conference

RedHill Biopharma To Present At The Rodman & Renshaw 19th Annual Global Investment Conference

RedHill Biopharma To Present At The Rodman & Renshaw 19th Annual Global Investment Conference

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

Biotech Movers: Red Hill Jumps After Securing Rights Sell GERD Treatment

A number of biotech-related stocks were down pre-market after announcing plans for public offerings.

RedHill Biopharma Announces U.S. Commercialization Agreement For FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules

RedHill Biopharma Announces U.S. Commercialization Agreement For FDA-Approved GI Product Esomeprazole Strontium Delayed-Release Capsules

RedHill Biopharma Provides 2017 Semi-Annual Business Update

RedHill Biopharma Provides 2017 Semi-Annual Business Update

RedHill Biopharma Announces Unanimous Positive DSMB Recommendation For Continuation Of The Phase III Study With RHB-104 For Crohn's Disease

RedHill Biopharma Announces Unanimous Positive DSMB Recommendation For Continuation Of The Phase III Study With RHB-104 For Crohn's Disease

RedHill Biopharma Reports 2017 Second Quarter Financial Results

RedHill Biopharma Reports 2017 Second Quarter Financial Results

RedHill Biopharma To Host Second Quarter 2017 Financial Results Conference Call On July 25, 2017

RedHill Biopharma To Host Second Quarter 2017 Financial Results Conference Call On July 25, 2017

RedHill Biopharma Announces Last Patient Visit In BEKINDA® Phase II Study For IBS-D

RedHill Biopharma Announces Last Patient Visit In BEKINDA® Phase II Study For IBS-D

RedHill Biopharma Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn's Disease

RedHill Biopharma Announces Expected Timeline For DSMB Meeting And Provides Update On Enrollment In The RHB-104 Phase III Study For Crohn's Disease

RedHill Biopharma To Host Conference Call On Successful Phase III Top-Line Results With BEKINDA® For Acute Gastroenteritis

RedHill Biopharma Announces Confirmatory Phase III Study Initiated With RHB-105 (TALICIA™) For H. Pylori Infection

RedHill Biopharma Announces Successful Phase III Top-Line Results With BEKINDA® For Acute Gastroenteritis

RedHill Biopharma Initiates Promotion Of Donnatal® And EnteraGam® In The U.S.

RedHill Biopharma To Present At The 2017 BIO International Convention

RedHill Biopharma Announces Poster Presentation Of The Positive RHB-105 Phase III Results For H. Pylori Infection At Digestive Disease Week 2017

RedHill Biopharma Reports 2017 First Quarter Financial Results

RedHill Biopharma To Host First Quarter 2017 Financial Results Conference Call On May 3, 2017

RedHill Biopharma Announces Enrollment Of Last Patient In The BEKINDA® Phase II Study For IBS-D

RedHill Biopharma Announces Peer-Reviewed Publication Of The Positive YELIVA® Phase I Study Results In Advanced Solid Tumors

RedHill Biopharma To Host R&D Day On BEKINDA® For Acute Gastroenteritis And IBS-D

RedHill Biopharma Receives Notice Of Allowance For Two Additional U.S. Patents Covering BEKINDA®

RedHill Biopharma And IntelGenx Announce Marketing Approval Of RIZAPORT® For Migraines In Luxembourg

RedHill Biopharma Announces Exclusive U.S. License From Entera Health For Commercial GI Product EnteraGam®

RedHill Biopharma Receives FDA Orphan Drug Designation For YELIVA® For The Treatment Of Cholangiocarcinoma

RedHill Biopharma To Present At BioCentury Future Leaders In The Biotech Industry Conference

RedHill Biopharma To Present At The 2017 MAP Conference

Load More
Quant Rating on 3:59 PM EDT 9/20/2017

D

(Sell)

From Our Partners

Redhill (RDHL) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
SeekingAlpha

RedHill nabs U.S. rights to GERD med Esomeprazole Strontium DR Capsules; shares up 4% premarket
SeekingAlpha

Redhill's Dilution Remedy, A Work In Process
SeekingAlpha

RedHill's late-stage study of RHB-104 in Crohn's to continue as planned, enrollment to be completed in H1 2018; shares ease 2% on extended completion date
SeekingAlpha

2 Small-Cap Biotechs To Put On Your Radar
SeekingAlpha

Healthcare - Top 5 Gainers / Losers as of 11:00 am
SeekingAlpha

RedHill Bio Q2 loss widens 68%
SeekingAlpha

Redhill beats by $0.52, beats on revenue
SeekingAlpha

3 Things In Biotech You Should Learn Today: July 20, 2017
SeekingAlpha

RedHill updates on Crohn's candidate RHB-104, second DSMB review later this month
SeekingAlpha

Q3 Biotech Catalyst Watch: Phase 3 Data Releases (Part 2)
SeekingAlpha

BEKINDA Phase III GUARD Study Top-Line Results
SeekingAlpha

RedHill Biopharma (RDHL) Presents At BIO International Conference 2017 - Slideshow
SeekingAlpha

RedHill launches late-stage study of H. pylori killer RHB-105; shares down 2% premarket on carryover from yesterday's reversal
SeekingAlpha

RedHill's Bekinda successful in late-stage gastroenteritis study; shares ahead 7% premarket
SeekingAlpha
TheStreet Quant Rating: D (Sell)

Get the (RDHL)
Report Here

Watchlist

Trending
Gold, Google, SEC Hack - 5 Things You Must Know Before the Market Opens Thursday
With Fed Meeting Over, Stocks Search for a Fresh Catalyst
European Stocks Called Higher After Fed Rate Path Lifts U.S. Dollar
Apple Falls Below 50-Day Moving Average - Why the Next Move Could Be Surprising
What's Up With Apple?